【2h】

ATG5 knockout promotes paclitaxel sensitivity in drug-resistant cells via induction of necrotic cell death

机译:ATG5敲除通过诱导坏死细胞死亡促进耐药细胞中的紫杉醇敏感性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Autophagy regulators are often effective as potential cancer therapeutic agents. Here, we investigated paclitaxel sensitivity in cells with knockout (KO) of gene. The KO in multidrug resistant v-Ha-ras-transformed NIH 3T3 cells (Ras-NIH 3T3/Mdr) was generated using the CRISPR/Cas9 technology. The qPCR and LC3 immunoblot confirmed knockout of the gene and protein of ATG5, respectively. The KO restored the sensitivity of Ras-NIH 3T3/Mdr cells to paclitaxel. Interestingly, overexpression restored autophagy function in KO cells, but failed to rescue paclitaxel resistance. These results raise the possibility that low level of resistance to paclitaxel in KO cells may be related to other roles of independent of its function in autophagy. The KO significantly induced a G /M arrest in cell cycle progression. Additionally, KO caused necrosis of a high proportion of cells after paclitaxel treatment. These data suggest that the difference in sensitivity to paclitaxel between KO and their parental MDR cells may result from the disparity in the proportions of necrotic cells in both populations. Thus, our results demonstrate that the KO in paclitaxel resistant cells leads to a marked G /M arrest and sensitizes cells to paclitaxel-induced necrosis.
机译:自噬调节剂通常作为潜在的癌症治疗剂有效。在这里,我们调查了基因敲除(KO)细胞中紫杉醇的敏感性。使用CRISPR / Cas9技术在多药抗v-Ha-ras转化的NIH 3T3细胞(Ras-NIH 3T3 / Mdr)中生成KO。 qPCR和LC3免疫印迹分别证实了ATG5的基因和蛋白的敲除。 KO恢复了Ras-NIH 3T3 / Mdr细胞对紫杉醇的敏感性。有趣的是,过表达恢复了KO细胞的自噬功能,但未能挽救紫杉醇耐药性。这些结果增加了可能性,即KO细胞中对紫杉醇的低水平耐药性可能与其独立于自噬功能的其他作用有关。 KO明显诱导细胞周期进程中的G / M停滞。另外,KO在紫杉醇治疗后引起高比例的细胞坏死。这些数据表明,KO及其亲代MDR细胞对紫杉醇敏感性的差异可能是由于两个种群中坏死细胞比例的差异所致。因此,我们的结果表明,紫杉醇抗性细胞中的KO导致明显的G / M停滞,并使细胞对紫杉醇诱导的坏死敏感。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号